Peer-influenced content. Sources you trust. No registration required. This is HCN.
Consultant360
A conversation with Ann Marie Navar, MD, PhD, associate professor of cardiology at UT Southwestern in Dallas, Texas and associate editor of JAMA Cardiology, who discusses common statin-related myths, the safety of statin therapy, and reliable sources of information for patients.
Cardiology July 19th 2022
MDLinx
In a look “Beyond the Guidelines,” a preventive cardiologist and a general internist discuss their approach in the case of a 57-year-old woman with high cholesterol and a family history of heart disease.
Cardiology June 23rd 2022
A meta-analysis published in JAMA Internal Medicine has concluded that the link between statin-induced LDL lowering and reduction of CV outcomes may not be as robust as previously assumed. According to the researchers, the absolute risk reduction associated with statin use for all-cause mortality was 0.8% (95% CI, 0.4-1.2), whereas for MI it was 1.3% (95% CI, 0.9-1.7) and for stroke it was 0.4% (95% CI, 0.2-0.6). Absolute risk reduction figures were slightly higher for secondary prevention than for primary prevention.
Cardiology March 22nd 2022
JAMA Network
Publication: JAMA Internal MedicineDesign: Retrospective cohort study of more than 83,000 propensity-scored matched pairs over a 12-year period.Results: Diabetes progression was significantly greater among diabetes patients using statins vs. those not using statins.
Cardiology October 12th 2021